Drugs / PF-07328948
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07508228 | Apr → Sep 2026 expected | — | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07455240 | Mar → Apr 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07315360 | Jan 2026 → Mar 2027 expected | impaired renal function disease | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07269301 | Dec 2025 → Feb 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT06837259 | Mar → Jun 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05807490 | Apr 2023 → Jul 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05654181 | Oct 2022 → May 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06991257 | Jun 2025 → Nov 2027 expected | heart failure | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07328948 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05807490 ↗ |
| Action | Inhibit | “AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948” NCT06991257 ↗ |
| Route | Oral | “investigational drug administered orally” NCT05654181 ↗ |